Topical ciprofloxacin treatment of Pseudomonas keratitis in rabbits

Arch Ophthalmol. 1988 Oct;106(10):1444-6. doi: 10.1001/archopht.1988.01060140608032.


Ciprofloxacin is a new quinolone antibiotic that is highly active in vitro against Pseudomonas aeruginosa. A rabbit model of bacterial keratitis was used to assess the in vivo efficacy of topical ciprofloxacin. Albino rabbits received intrastromal injections of 5 X 10(2) aminoglycoside-resistant P aeruginosa organisms. At five hours after inoculation, ciprofloxacin (3 mg/mL) therapy was initiated (one drop every 30 minutes for 12 hours). Corneal tissue was then excised for bacterial colony counts. No organisms were recovered from ciprofloxacin-treated eyes, compared with an average of 3.1 X 10(7) organisms per milliliter recovered from untreated controls. This model suggests that topical ciprofloxacin may be clinically useful in the treatment of aminoglycoside-resistant P aeruginosa keratitis.

MeSH terms

  • Administration, Topical
  • Animals
  • Aqueous Humor / metabolism
  • Ciprofloxacin / administration & dosage*
  • Ciprofloxacin / pharmacokinetics
  • Cornea / metabolism
  • Keratitis / drug therapy*
  • Ophthalmic Solutions
  • Pseudomonas Infections / drug therapy*
  • Pseudomonas aeruginosa
  • Rabbits


  • Ophthalmic Solutions
  • Ciprofloxacin